Equities

Medistim ASA

Medistim ASA

Actions
Health CareMedical Equipment and Services
  • Price (NOK)176.50
  • Today's Change-4.50 / -2.49%
  • Shares traded6.77k
  • 1 Year change-33.14%
  • Beta--
Data delayed at least 15 minutes, as of May 03 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Medistim ASA is a Norway-based company engaged in the provision of medical equipment and technology. It develops, manufactures and distributes medical devices that measure blood flow and visualize atherosclerosis, and thereby help improve the outcome of cardiac and vascular surgery. The Company provides Transit Time Flow Measurement (TTFM) and ultrasound imaging to the global market to enable medical professionals to reduce risk and enhance quality of cardiac, vascular and transplant surgery. Medistim’s activities are divided into two business units: Own Products Category and Third-Party Products Category. Furthermore, the Company has several subsidiaries, including Medistim USA Inc, Medistim Norge AS and Medistim Japan KK.

  • Revenue in NOK (TTM)530.89m
  • Net income in NOK102.54m
  • Incorporated1995
  • Employees152.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Pulsion Medical Systems SE370.84m63.31m1.69bn66.0026.725.2121.224.560.65490.65493.843.360.97111.773.88479,840.0016.5820.3721.2431.1763.6655.9617.0724.121.7715.740.001,227.726.103.02-8.06----0.00
Creo Medical Group PLC399.12m-342.74m1.73bn279.00--1.78--4.33-0.1139-0.11390.1260.19660.33181.874.14102,926.10-28.49---34.24--48.11---85.87--3.45--0.1177--7.98---9.52------
Stille AB296.53m26.79m1.84bn106.0038.411.6244.706.225.315.3158.76126.110.514----2,782,019.004.647.035.218.1944.8243.939.049.856.543.360.0021.9819.7016.78-2.485.3423.62--
Onward Medical NV0.00-423.67m1.97bn99.00--8.20-----1.20-1.200.000.5940.00----0.00-60.19-55.70-68.71-61.60-------79,513.95---58.040.4848---34.62---10.40--32.59--
Prim SA2.54bn148.39m1.99bn900.0013.421.357.500.78690.7450.74512.737.401.121.994.10240,567.406.586.689.248.9037.9338.115.856.431.22--0.1681--9.7710.0051.02-2.1412.86--
Bactiguard Holding AB222.04m-126.89m2.25bn191.00--7.35--10.12-3.60-3.606.309.800.30354.286.001,017,544.00-17.35-7.56-19.82-8.8129.8747.91-57.15-26.281.64-11.900.4129---11.966.46-161.71--8.43--
Sedana Medical AB (publ)165.83m-22.96m2.27bn83.00--2.2833,161.0213.67-0.2299-0.22991.669.950.15641.248.102,087,443.00-2.17-5.77-2.28-6.0870.5064.06-13.85-36.137.38--0.0043--25.2321.5918.90--42.12--
Detection Technology Oyj-1.17tn-1.17tn2.70bn478.00--3.17----------4.97----------9.34--11.96--47.44--8.223.13--0.08153.455.292.027.55-18.03-14.88-9.55
Semperit Holding AG8.44bn294.27m2.79bn4.58k9.450.56113.820.3311.23-0.816235.1720.670.80984.688.24157,578.902.795.253.607.3222.4624.793.455.591.384.920.342686.85-7.54-3.87-34.59---7.21--
Tristel Plc539.18m82.43m3.00bn213.0036.817.0425.695.570.12560.12560.82190.65670.9921.516.26185,394.4015.178.8617.1010.2482.5980.6315.2910.633.93411.730.1605109.9915.7010.14351.986.409.8818.05
Nyxoah SA50.91m-506.01m3.15bn147.00--2.75--61.96-1.55-1.550.15553.420.03220.78912.0629,618.53-31.98-23.73-35.88-25.9861.9162.42-993.86-1,469.594.50--0.1147--40.99---38.39--100.58--
BICO Group AB2.26bn-1.71bn3.22bn884.00--0.6701--1.42-23.61-27.6631.6069.180.24872.243.062,545,136.00-18.77---20.89--52.34---75.47--1.91-1.050.2852--6.09---1,889.33------
Medistim ASA530.89m102.54m3.24bn152.0031.507.5225.536.105.605.6029.0123.481.030.77656.153,492,704.0019.9522.9324.0728.5279.0278.2519.3120.642.99--0.020675.257.0010.06-8.9112.720.03314.87
Lumibird SA2.38bn83.44m3.37bn1.05k35.961.4811.751.410.35590.35599.148.620.52381.094.05193,497.101.833.132.443.9961.6861.763.505.891.622.470.42870.006.6015.12-37.23-2.4718.34--
COLTENE Holding AG2.92bn143.57m3.79bn1.20k26.383.2616.791.302.002.0040.6216.211.331.406.58201,937.606.5310.4810.9018.7464.2462.684.927.470.80455.620.317279.94-9.133.54-54.05-6.81-7.72-7.79
IVF Hartmann Holding AG1.78bn182.04m3.98bn304.0021.872.1916.022.246.316.3161.6363.070.80153.088.46486,687.508.217.299.998.9053.9053.2910.248.303.89--0.005652.16-1.792.0934.951.49-14.8326.82
Data as of May 03 2024. Currency figures normalised to Medistim ASA's reporting currency: Norwegian Krone NOK

Institutional shareholders

51.34%Per cent of shares held by top holders
HolderShares% Held
Aeternum Management ASas of 27 Sep 20231.90m10.36%
SEB Investment Management AB (Denmark)as of 28 Mar 20241.42m7.76%
ODIN Forvaltning ASas of 14 Apr 20231.20m6.54%
Swedbank Robur Fonder ABas of 29 Feb 20241.16m6.30%
Invesco Advisers, Inc.as of 31 Mar 2024910.00k4.96%
Joh. Berenberg, Gossler & Co. KG (Investment Management)as of 30 Dec 2022801.80k4.37%
Fidelity Management & Research Co. LLCas of 31 Mar 2024617.55k3.37%
ODIN Forvaltning AS (Sweden)as of 14 Apr 2023600.00k3.27%
SEB Investment Management ABas of 28 Mar 2024416.83k2.27%
Skandinaviska Enskilda Banken AB (Denmark)as of 28 Mar 2024389.97k2.13%
More ▼
Data from 31 Dec 2023 - 28 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.